
Sign up to save your podcasts
Or


The risk of cardiovascular disease is twice as great among patients living with HIV, and this could partly be due to traditional risk factors, along with nontraditional risk factors. Here to discuss the results from the REPRIEVE study with Dr. Mary Katherine Cheeley is Dr. Steve Grinspoon, Co-Principal Investigator and Professor of Medicine at Harvard Medical School in Boston.
Although the rate of new HIV diagnoses in the United States is steadily declining, people in prisons are still disproportionately living with the virus, which is why researchers at Temple University are now developing an app aimed at improving HIV prevention and substance use treatment access for incarcerated women in Philadelphia. To learn more about this research, Dr. Mary Katherine Cheeley is joined by Dr. Sarah Bauerle Bass, Associate Professor of Social and Behavioral Sciences and the Director of Risk Communication Laboratory at Temple University.
Scientists at Temple University’s Lewis Katz School of Medicine have identified a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. Find out how this recent discovery could get us one step closer to a cure for HIV with Dr. Charles Turck and Dr. Kamel Khalili, the Laura H. Carnell Professor in the Department of Neuroscience and Chair of the Department of Microbiology, Immunology & Inflammation.
In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.
Researchers from the National Institutes of Health (NIH) found that 100 percent of the participants in this study had fatigue and experienced cognitive difficulties. So what can we learn from this new research to help us diagnose and treat patients with disabling neurological symptoms after they had COVID-19? To discuss the findings, Dr. Charles Turck is joined by Dr. Avindra Nath, Clinical Director of the National Institute of Neurological Disorders and Stroke.
How are standard versus adjuvanted influenza vaccines made? Here to break down the manufacturing process for these types of influenza vaccines is primary care physician Dr. Jason Goldman.
Emerging treatment options have helped patients with HIV live longer, but the aging population faces its own unique challenges. To explore how we can combat these challenges—including the ongoing stigma around HIV—Dr. Charles Turck is joined by Dr. Andrew Clark, who is the Global Medical Lead at ViiV Healthcare.
COVID-19 viral rebound infections continue to impact patients and challenge clinicians. To help us better understand why some patients experience it—and how antiviral medication plays a role—Dr. Charles Turck and Dr. Jonathan Li explore COVID-19 rebound infections and antiviral treatment nirmatrelvir/ritonavir.
Diagnosing pneumonia can be challenging, but the CAP guidelines offer recommendations to improve the detection of this infection. To find out more about the recommendations, Dr. Randy Young and Dr. Daniel Feinstein, a Physician Executive at Novant Health, dive into testing for pneumonia.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by bioMèrieux.
Why are we currently facing a tripledemic? Joining Dr. Jennifer Caudle to uncover what has led to this dramatic increase in COVID-19, RSV, and the flu—and share strategies to combat this tripledemic—is ReachMD Host Dr. Jennifer Shu, a pediatrician at Children’s Medical Group in Atlanta, Georgia.